Xeltis has exceeded 50% patient enrolment in the US pivotal trial evaluating aXess, its
restorative vascular access device for haemodialysis.
More than half of the planned 140 patients have now been recruited across 20 clinical centres in
the United States. The prospective, multicentre study is assessing the safety, performance and
patency of aXess in adults with end-stage renal disease who require vascular access for haemodialysis. Patients will be followed for up to five years.
Reaching the halfway point is an important operational milestone for Xeltis. Patient recruitment remains one of the biggest causes of delays in medical device trials, particularly when studies involve complex patients, multiple centres and long-term follow-up.
However, the significance of aXess extends beyond trial enrolment.
Unlike a conventional synthetic vascular graft designed to remain permanently in the body, aXess uses a bioabsorbable implant intended to provide initial vascular access while encouraging the patient’s own tissue to form a new living vessel.
Over time, the implant is designed to be absorbed, leaving behind functional tissue
created through Xeltis’ Endogenous Tissue Restoration technology.
This represents an increasingly important direction for cardiovascular innovation.
For decades, the medical device industry has largely focused on replacing damaged
anatomy, supporting it mechanically or permanently implanting synthetic materials. Regenerative technologies propose something more ambitious: providing a temporary
structure that helps the body rebuild itself.
It is an attractive proposition, particularly in haemodialysis, where vascular access
remains one of the most persistent challenges facing patients and clinicians.
Patients with end-stage renal disease may require dialysis several times each week, placing enormous strain on vascular access sites. Existing options, including arteriovenous fistulas and synthetic grafts, can be affected by complications such as infection, thrombosis, narrowing and repeated interventions.
A vascular access conduit capable of transforming into living tissue could potentially
offer a more durable and biologically compatible alternative.
But this is also where the industry should remain cautious.
“Regenerative” is rapidly becoming one of MedTech’s most attractive labels. It is a
powerful story for investors, clinicians and patients, but biology is rarely as predictable
as engineering.
Creating tissue is not automatically the same as creating reliable, durable and clinically
superior tissue. The real test will be whether the vessel formed through aXess can consistently withstand years of repeated needle access while reducing complications and interventions compared with established alternatives.
Exceeding 50% enrolment is therefore encouraging, but it should not be confused with
clinical validation.
FDA Breakthrough Device Designation, granted to aXess in November 2024, may
support more frequent interaction with the regulator and a more efficient review
process. It does not, however, guarantee approval or commercial success.
That distinction matters because MedTech has occasionally become too enthusiastic
about early regulatory milestones. Breakthrough designation is meaningful, but long
term clinical outcomes, physician confidence, procedural integration and health economic value will ultimately determine whether a technology changes practice.
Xeltis has nevertheless moved beyond being purely a regenerative technology concept.
The company has reported clinical progress in Europe and recently began the broader
European commercial rollout of aXess following its first commercial implantation. That
means the technology is now entering the more difficult phase of proving that scientific
innovation can translate into routine clinical adoption.
For the wider cardiovascular sector, aXess is worth watching because it reflects a
potential change in how implants are designed.
The future may not belong solely to smaller devices, smarter devices or more minimally
invasive devices. It may increasingly belong to implants that are only intended to exist
temporarily, supporting the body before gradually disappearing.
That is a compelling vision, but one that must be supported by long-term evidence
rather than regenerative language alone.
For now, exceeding 50% enrolment represents a significant step forward for Xeltis and
its US regulatory programme. The next and more important question is whether aXess
can demonstrate that a living vessel is not simply more biologically elegant than a
permanent implant, but meaningfully better for dialysis patients.
Congratulations to Eliane Schutte, Paulo Neves, Alexander Goemans, Rob Eyers and
the wider Xeltis team on reaching this milestone.
